Senestech, Inc. (NASDAQ:SNES – Get Free Report) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 12,817 shares, a drop of 27.3% from the December 31st total of 17,626 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 21,108 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 21,108 shares, the short-interest ratio is presently 0.6 days. Approximately 0.3% of the company’s stock are sold short.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senestech in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Senestech presently has an average rating of “Hold”.
Read Our Latest Research Report on SNES
Institutional Inflows and Outflows
Senestech Stock Performance
NASDAQ SNES opened at $1.85 on Monday. The company’s 50 day moving average is $2.36 and its 200-day moving average is $3.63. The company has a quick ratio of 14.73, a current ratio of 15.75 and a debt-to-equity ratio of 0.01. Senestech has a 12-month low of $1.30 and a 12-month high of $6.24. The firm has a market cap of $9.66 million, a P/E ratio of -0.51 and a beta of 0.22.
Senestech (NASDAQ:SNES – Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.07. The company had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.73 million. Senestech had a negative net margin of 253.54% and a negative return on equity of 98.35%. Sell-side analysts predict that Senestech will post -10.22 earnings per share for the current year.
About Senestech
SenesTech, Inc (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company’s core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.
The company’s flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction.
Read More
- Five stocks we like better than Senestech
- Trump just signed it
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Forget AI, This Will Be the Next Big Tech Breakthrough
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Refund From 1933: Trump’s Reset May Create Instant Wealth
Receive News & Ratings for Senestech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech and related companies with MarketBeat.com's FREE daily email newsletter.
